7-(4-Chloro-3,4-dihydropyrazol-2-yl)-3,3-dimethyl-1-(2-phenylethyl)pyrrolo[3,2-b]pyridin-2-one | 1314944-55-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 7-(4-Chloro-3,4-dihydropyrazol-2-yl)-3,3-dimethyl-1-(2-phenylethyl)pyrrolo[3,2-b]pyridin-2-one
• CAS: 1314944-55-2
• 化学式: C₂₀H₂₁ClN₄O
• 分子量: 368.866
• InChiKey: ZLKJUDKFNRQJPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  48.8
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• FUSED PYRIDINE DERIVATIVES
  申请人：Huang Zhenhua

  公开号：US20120289497A1

  公开（公告）日：2012-11-15

  Fused pyridine derivatives shown as the general formula (I), and their pharmaceutically acceptable salts, stereoisomers or solvates thereof are disclosed, which belong to the technical field of medicines. The R 1 , R 2 , R 3 , Q, X and Y substituents in formula (I) are defined as in the description. Also disclosed are the preparation methods, pharmaceutical compositions comprising the compounds and uses of the compounds in the manufacture of the medicine for the treatment and/or prevention of noninsulin-dependent diabetes, hyperglycemia, hyperlipidemia and insulin resistance.

  揭示了作为一般式(I)显示的融合吡啶衍生物以及它们的药用可接受盐、立体异构体或溶剂化物，属于药物技术领域。在式(I)中，R1、R2、R3、Q、X和Y的取代基的定义如描述中所述。还揭示了该化合物的制备方法、包含该化合物的药物组合物以及用于制造治疗和/或预防非胰岛素依赖性糖尿病、高血糖、高脂血症和胰岛素抵抗的药物的用途。
• US8680089B2
  申请人：——

  公开号：US8680089B2

  公开（公告）日：2014-03-25
• [EN] FUSED PYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRIDINE CONDENSÉS
  申请人：KBP BIOMEDICAL CO LTD

  公开号：WO2011085643A1

  公开（公告）日：2011-07-21

  Fused pyridine derivatives shown as the general formula (I), and their pharmaceutically acceptable salts, stereoisomers or solvates thereof are disclosed, which belong to the technical field of medicines. The R1, R2, R3, Q, X and Y substituents in formula (I) are defined as in the description. Also disclosed are the preparation methods, pharmaceutical compositions and uses of the compounds in the manufacture of the medicine for the treatment and/or prevention of noninsulin-dependent diabetes, hyperglycemia, hyperlipidemia and insulin resistance.